New UBC research reveals alternative route to rein in glioma cancer cells

New UBC research into brain cancer suggests treatments should target the cells around a tumor to stop it from spreading.

UBC research team Christian Naus, Wun Chey Sin and John Bechberger study glioma, the most aggressive form of adult brain cancer. Glioma has a low five-year survival rate of 30 per cent because it is difficult to completely remove cancer cells without compromising brain functions and chemotherapy and radiotherapy do not prevent the regrowth of remaining cancer cells.

With this new research, the team reveals an alternative route to rein in the glioma cancer cells. The cancerous cells mingle with astrocytes, a type of cell that regulates the environment in the brain to create favourable conditions for brain functions. The research team found that glioma cells can reprogram the astrocytes with little pieces of genetic code (microRNAs). Those codes act as master switches, turning specific sets of genes on and off.

"This is the first evidence that microRNA can go from glioma cells into astrocytes and reprogram them to provide an altered environment that stimulates tumor growth and invasion," said Naus, a professor in the Department of Cellular & Physiological Sciences in the Life Sciences Institute and an investigator with the Djavad Mowafaghian Centre for Brain Health.

"We should consider the possibility of creating a treatment that would temporarily modify the healthy astrocytes around the tumor so the cancer cells can't hijack them," said Sin, a research associate leading the glioma investigation in the Naus laboratory.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough in aging research: Blocking IL-11 extends lifespan and improves health in mice